co.don AG Shareholders' meeting adopts capital increase
(Thomson Reuters ONE) -
co.don AG /
co.don AG Shareholders' meeting adopts capital increase
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
* ?3.9 million fresh capital for the biopharma company
Teltow/Berlin On 8 August 2012 the shareholders' meeting of biopharmaceutical
company co.don AG (ISIN DE000A1K0227) approved a proposal for a capital increase
put forward by the Executive Board and Supervisory Board. The shareholders voted
to create new approved capital of ?3,554,292. This increases the company's share
capital from ?7,108,584 to ?10,662,876. Two investors have already committed to
purchase the 3,554,292 new shares at a price of ?1.10 per share. As a result of
acquiring the two new investors - TRANS NOVA INVESTMENTS LIMITED and OSEMIFARO
INVESTMENTS LTD - co.don AG will receive proceeds of around ?3.9 million.
"This new investment secures the funding of our company", said Dr. Andreas
Baltrusch, CEO of co.don AG. "In particular the fresh capital will cover the
substantial expenses for the two clinical trials needed to apply for approval by
the European Medicines Agency (EMA)."
Approval is a fundamental requirement for a European central marketing
authorisation and is mandatory from 2013. The company is working all out on
several pre-clinical and clinical trials for its main product, co.don
chondrosphere®. In 1997 co.don AG became the first company in Europe to receive
production authorisation for autologous chondrocyte transplants. More than
4,500 patients have been treated with its patented methods to date. Last year
co.don AG was voted Entrepreneur of the Year by the Association of East German
Savings Banks.
The shareholders' meeting also passed a resolution to expand the Supervisory
Board from three to six members. The newly elected Supervisory Board members are
Mr Thomas Krause, Potsdam, Mr Stig Jarle Petterson, Oslo and Dr. Andrei Petrov,
Moscow.
co.don AG is a leading innovator in the production of autologous chondrocyte
transplants and has continued its positive business development in 2012. In the
first half of 2012 revenue rose to ?1,251 million, an increase of some 7 per
cent on the same period last year. Sales in the domestic German market in
particular were up by more than 10 per cent in the first six months.
The attendance figures and the result of voting on the agenda items for the
shareholders' meeting can be found at:
http://www.codon.de/investors/shareholders-meeting.html?L=1
About co.don(®) AG:
The company is based in Teltow, Brandenburg, and was founded in 1993. Since
2001 the biopharmaceutical specialist has been listed on the Frankfurt Stock
Exchange (ISIN: DE000A1K0227). co.don AG(®) uses tissue engineering - the
cultivation and growth of autologous tissue cells - to develop innovative
products and therapeutic concepts for the orthopaedic and neurosurgical markets.
The cell-based biological drugs (autologous cell transplants for articular
cartilage and intervertebral disks) are produced without the use of antibiotics,
growth factors and genetic engineering. The Executive Board of co.don(®) AG is
made up of Dr Andreas Baltrusch (CEO) and Vilma Siodla (COO).
Further information is also available at: www.codon.de
Press contact
BrunoMedia GmbH
Gerd J. Gauger
Bonner Straße 328
50968 Cologne
Telephone: +49 221 348 038 10
Fax: +49 221348 038 41
Email: codon(at)brunomedia.de
Press release (PDF):
http://hugin.info/132731/R/1633012/523940.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: co.don AG via Thomson Reuters ONE
[HUG#1633012]
Unternehmensinformation / Kurzprofil:
Datum: 09.08.2012 - 12:39 Uhr
Sprache: Deutsch
News-ID 173304
Anzahl Zeichen: 4606
contact information:
Town:
Teltow
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 150 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"co.don AG Shareholders' meeting adopts capital increase"
steht unter der journalistisch-redaktionellen Verantwortung von
co.don AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
